Evidence map›Paper›PMID 38848145›Full record

ArticleAging2024

APOA5 alleviates reactive oxygen species to promote oxaliplatin resistance in PIK3CA-mutated colorectal cancer.

Yu-Lin Liu, Zhuo Xiang, Bo-Ya Zhang, Yu-Wei Zou, Gui-Lai Chen, Li Yin, Yan-Long Shi, Li-Li Xu, Jingwang Bi, Qiang Wang

RetractedAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Apolipoprotein A (ApoA) in Neurological Disorders: Connections and Insights.International journal of molecular sciences · 2025
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Yu-Lin LiuDepartment of Otolaryngology-Head and Neck Surgery, Shandong Provincial ENT Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250023, China.
Zhuo XiangDepartment of Otolaryngology-Head and Neck Surgery, Shandong Provincial ENT Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250023, China.
Bo-Ya ZhangChina Key Laboratory of Marine Drugs, The Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Yu-Wei ZouDepartment of Pathology, Affiliated Hospital of Medical College, Qingdao University, Qingdao 266003, China.
Gui-Lai ChenDepartment of Otolaryngology-Head and Neck Surgery, Shandong Provincial ENT Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250023, China.
Li YinDepartment of Otolaryngology-Head and Neck Surgery, Shandong Provincial ENT Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250023, China.
Yan-Long ShiDepartment of Oncology, 960 Hospital of People’s Liberation Army, Jinan 250031, China.
Li-Li XuDepartment of Pathology, Navy 971 People’s Liberation Army Hospital, Qingdao 266071, China.
Jingwang BiDepartment of Otolaryngology-Head and Neck Surgery, Shandong Provincial ENT Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250023, China.
Qiang WangDepartment of Otolaryngology-Head and Neck Surgery, Shandong Provincial ENT Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250023, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although platinum-based chemotherapy is the frontline regimen for colorectal cancer (CRC), drug resistance remains a major challenge affecting its therapeutic efficiency. However, there is limited research on the correlation between chemotherapy resistance and lipid metabolism, including PIK3CA mutant tumors. In this present study, we found that PIK3CA-E545K mutation attenuated cell apoptosis and increased the cell viability of CRC with L-OHP treatment

Indexed as

Apolipoprotein A-VClass I Phosphatidylinositol 3-KinasesColorectal NeoplasmsDrug Resistance, NeoplasmMutationOxaliplatinReactive Oxygen SpeciesAnimalsAntineoplastic AgentsApoptosisCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMaleMiceAntineoplastic AgentsAPOA5 protein, humanApolipoprotein A-VClass I Phosphatidylinositol 3-KinasesOxaliplatinPIK3CA protein, humanReactive Oxygen SpeciesSREBF1 protein, humanSterol Regulatory Element Binding Protein 1apolipoprotein A5colorectal canceroxaliplatin resistancePIK3CA mutationreactive oxygen species

Identifiers

PMID38848145
PMCPMC11210231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.